CytoDyn (OTCQB:CYDY) is collaborating with the U.K.’s Department of Health to provide emergency access to leronlimab, an investigational medicine for COVID-19.
The submission to Medicines and Healthcare
Products Regulatory Agency (MHRA) is expected soon to include clinical
trial sites in the U.K.
U.K. representatives are coordinating with
CytoDyn’s international clinical research organization, Amarex Clinical
Research, to prepare the requisite clinical agreements and to prepare
for timely delivery of leronlimab.
The FDA has cleared the Company to initiate a Phase 2b/3 clinical trial COVID-19 patients for which enrollment is now underway.
https://seekingalpha.com/news/3558860-cytodyn-to-supply-leronlimab-to-uk-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.